

Tebentafusp IMCgp100-202

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



Tebentafusp IMCgp100-202

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers  
 Therapeutic Indication: Treatment of human leukocyte antigen (HLA)-A\*02:01-positive adult patients with unresectable or metastatic uveal melanoma  
 Experimental Arm: Tebentafusp  
 Control Arm: Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab)

